

2016feb_rna_uk.jpgSMi presents the 7th annual conference:

RNA Therapeutics

Sustainable production of targeted delivery and mRNA

15 – 16 February 2016

Holiday Inn Kensington Forum, London UK

<http://www.therapeutics-rna.com/inderscience>

Bringing new concepts of functionalised nanoparticles for targeted delivery, SMI's 7th annual RNA Therapeutics conference will feature a mix of case study-led presentations, panel debates, interactive workshops and keynote addresses tailored for an audience of professionals and research scientists looking to develop and commercialise novel RNA therapeutics and delivery systems.

This exciting programme for 2016 will show case new developments in messenger RNA-based therapeutics and anti-sense oligonucleotide-conjugates, including mRNA as data carriers, optimisation of immune response with pre-clinical and clinical results.

Join us next February to expand your scientific horizons on emerging concepts in nanoparticle delivery systems, companion diagnostics and aptamer-conjugates. Plus, we'll be honing in on key developments in under-met areas such as: Targeted delivery beyond the liver, and the regulatory minefield that lies ahead in the evolving sphere of nanotechnology and delivery devices.

Reasons to Attend:

- Learn new pre-clinical and clinical developments with antisense oligonucleotide-based delivery
- Rationalise how to control PK and PD variables of RNAi effector delivery in vivo
- Gain new insights of optimising mRNA therapeutics and delivery methods
- Understand industry hurdles of commercialisation and distinguishing regulatory compliance of nanoparticle-system delivery devices from therapeutics
- Discover new avenues in formulation and aptamer-conjugates

Key Speakers Include:

- Ryszard Kole, Distinguished Scientist, Sarepta Therapeutics
- Nagy Habib, Professor of Surgery, Chairman & Co-founder Imperial College London, MiNA Therapeutics
- Punit Seth, Executive Director, Isis Pharmaceuticals
- Mustafa Diken, Deputy Vice President, Immunotherapies and Preclinical Research, BioNTech AG
- Christian Schetter, Chief Executive Office and Managing Director, Rigontech GmbH
- Cristianne Rijcken, CSO, Cristal Therapeutics
- Heinrich Haas, Vice President RNA Formulation & Drug Delivery, BioNTech AG
- Brian Kelly, Associate, Covington & Burling LLP

For further details and to register, visit the website at <http://www.therapeutics-rna.com/inderscience>